MedTrace Logo

Female Fertility, Environmental Agents and Stress Oxidant

NCT04866329 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-07-25

No results posted yet for this study

Summary

Synthetic products used in industrial, pharmaceutical, agro-alimentary or agricultural fields are found in our environment. Thus, humans could be simultaneously exposed to several of these pollutants. Furthermore, these environmental agents exert or could exert adverse actions on fertility, by altering gamete and embryo quality through endocrine disruptor effects or through increase in oxidative stress in gonads (cellular pathway known to be involved in several human reproductive pathologies).

In this context, the objectives of the present project are to obtain descriptive and analytical data on woman and oocyte exposure to several environmental agents (bisphenols, ethynylestradiol and glyphosate). The relation between these pollutant measures in follicular fluid and urine (from women receiving follow-up of in vitro fertilization (IVF) protocol in the University hospital of Tours, France) and the oocyte quality, the IVF and pregnancy successes will be studied. Several oxidative stress biomarkers in blood and follicular fluid will be also measured for these women, who will complete a questionnaire on their lifestyles. Finally, thanks to in vitro approaches, the effects and the mechanisms of action (including oxidative stress) of these pollutants (alone or in cocktails) will be studied on granulosa cells from these patients.

Conditions

  • Female Infertility

Interventions

OTHER

Blood sample

Additional blood sampling at the end of ovarian stimulation monitoring (the eve of the oocyte pick-up)

OTHER

Urine sample

Collection of the first urine in the morning on the day of the oocyte pick-up

OTHER

Follicular fluid and granulosa cells sample

Collection of follicular fluid and granulosa cells during oocyte pick-up.

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Fabrice GUERIF, MD-PhD · University Hospital, Tours

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-08
Primary Completion
2026-12-08
Completion
2027-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04866329 on ClinicalTrials.gov